Trial Continuity in the Face of a Pandemic
The emerging Coronavirus (COVID-19) is impacting clinical trial oversight, primarily on-site monitoring. The Association of Clinical Research Organizations (ACRO) recommends that sponsors, CROs, and sites introduce emergency interim measures so that clinical trial monitoring is maintained.
While social distancing and isolation are paramount, clinical trials must adapt to remain viable. Remarque Systems supports alternative monitoring procedures that ensure social distancing while keeping current trials on track. Remarque can identify and prioritize sites, and associated data, that are likely to have significant impact on study data quality.
Download our eBook Clinical Trial Management in the era of COVID-19: Alternative Monitoring to learn how risk-based quality management (RBQM) can help yield more efficient, effective results for your clinical trial using a combination of on-site, remote, and centralized monitoring. You’ll learn:
- How to ensure patient safety without solely relying on on-site monitoring and high SDV
- Why regulators are recommending a flexible, trial-specific approach based on risk
- Steps to effectively implementing RBQM
